[go: up one dir, main page]

BR9916270A - Combinação de cerivastatina e fibratos - Google Patents

Combinação de cerivastatina e fibratos

Info

Publication number
BR9916270A
BR9916270A BR9916270-9A BR9916270A BR9916270A BR 9916270 A BR9916270 A BR 9916270A BR 9916270 A BR9916270 A BR 9916270A BR 9916270 A BR9916270 A BR 9916270A
Authority
BR
Brazil
Prior art keywords
fibrates
cerivastatin
combination
well
diseases
Prior art date
Application number
BR9916270-9A
Other languages
English (en)
Inventor
Joachim Ippen
Uirike Schopen
Reiner Ziegler
Fritz Schueckler
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BR9916270A publication Critical patent/BR9916270A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)

Abstract

Patente de Invenção: <B>"COMBINAçãO DE CERIVASTATINA E FIBRATOS"<D>. A presente invenção refere-se à combinação do inibidor de 3-hidróxi-3-3metil-glutarila-coenzima A (HMG-CoA-Inhibitors) cerivastatina com fibratos e seu emprego na profilaxia e tratamento de distúrbios e doenças do metabolismo dos lipídios, bem como de doenças causadas pelo mesmo.
BR9916270-9A 1998-12-18 1999-12-06 Combinação de cerivastatina e fibratos BR9916270A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19858789A DE19858789A1 (de) 1998-12-18 1998-12-18 Kombination von Cerivastatin und Fibraten
PCT/EP1999/009524 WO2000037078A1 (de) 1998-12-18 1999-12-06 Kombination von cerivastatin und fibraten

Publications (1)

Publication Number Publication Date
BR9916270A true BR9916270A (pt) 2001-09-04

Family

ID=7891784

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9916270-9A BR9916270A (pt) 1998-12-18 1999-12-06 Combinação de cerivastatina e fibratos

Country Status (19)

Country Link
US (1) US6511985B1 (pt)
EP (1) EP1140082A1 (pt)
KR (1) KR20010093845A (pt)
CN (1) CN1330544A (pt)
AR (1) AR021643A1 (pt)
AU (1) AU3035600A (pt)
BR (1) BR9916270A (pt)
CA (1) CA2355295A1 (pt)
CO (1) CO5160272A1 (pt)
DE (1) DE19858789A1 (pt)
GT (1) GT199900214A (pt)
HN (1) HN1999000208A (pt)
IL (1) IL143221A0 (pt)
PE (1) PE20001325A1 (pt)
PL (1) PL349389A1 (pt)
SV (1) SV1999000250A (pt)
TR (1) TR200101722T2 (pt)
WO (1) WO2000037078A1 (pt)
ZA (1) ZA200103918B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6294501A (en) 2000-09-20 2002-04-02 Rtp Pharma Inc Spray drying process and compositions of fenofibrate
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
RS50406B (sr) 2001-01-26 2009-12-31 Schering Corporation, Upotreba supstituisanih jedinjenja azetidinona za lečenje sitosterolemije
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
SI1413331T1 (sl) 2001-01-26 2008-02-29 Schering Corp Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije
PL202778B1 (pl) * 2001-02-22 2009-07-31 Skyepharma Canada Inc Postać dawkowana kombinacji statyny i fenofibratu, sposób jej wytwarzania i zastosowanie
US20050032878A1 (en) 2001-08-07 2005-02-10 Arthur Deboeck Oral pharmaceutical composition containing a combination pparalpha and a hmg-coa reductase inhibitor
WO2003013607A1 (en) * 2001-08-07 2003-02-20 Galephar M/F ORAL PHARMACEUTICAL COMPOSITION CONTAINING A COMBINATION OF FENOFIBRATE AND A HMG-CoA REDUCTASE INHIBITOR
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
MXPA04002573A (es) 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
DE10200138A1 (de) * 2002-01-04 2003-07-17 Karl Winkler Kombination von einem PPAR-Agonisten mit PPAR-alpha Aktivität mit einem Induktor des LDL-Rezeptors
EP1562582A1 (en) 2002-11-06 2005-08-17 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
US7411045B2 (en) * 2002-11-19 2008-08-12 A&G Pharmaceutical, Inc. Autocrine growth factor receptor antibodies and methods
ES2311806T3 (es) 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
US7192944B2 (en) 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CA2526730A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives
CA2543596A1 (en) * 2003-11-07 2005-05-26 Jj Pharma, Inc. Hdl-boosting combination therapy complexes
AU2006212609A1 (en) * 2005-02-10 2006-08-17 Lifecycle Pharma A/S A stable pharmaceutical composition comprising a fixed dose combination of fenofibrate and an HMG-CoA reductase inhibitor
BRPI0618379A2 (pt) * 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
CL2007000667A1 (es) * 2006-03-14 2008-03-14 Ranbaxi Lab Ltd Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e
US20070269503A1 (en) * 2006-05-16 2007-11-22 James Walter Burgess Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof
JP2009543773A (ja) * 2006-07-14 2009-12-10 ランバクシー ラボラトリーズ リミテッド ＨＭＧ−ＣｏＡレダクターゼ阻害剤の多形体及びその使用
CA2657394A1 (en) 2006-08-04 2008-02-07 Aska Pharmaceutical Co., Ltd. Preparation containing fibrate agent and process for producing the same
TWI407955B (zh) 2007-03-29 2013-09-11 Kowa Co 高脂血症之預防及／或治療劑
WO2023146320A1 (ko) * 2022-01-28 2023-08-03 동광제약 주식회사 로수바스타틴 또는 이의 약학적으로 허용되는 염 및 페노피브레이트를 함유하는 캡슐 제제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2494112B1 (pt) 1980-11-19 1986-01-10 Laruelle Claude
WO1988005296A2 (en) 1987-01-27 1988-07-28 Warner-Lambert Company Lpid regulating compositions
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
CA2039763A1 (en) * 1990-04-30 1991-10-31 Henry Y. Pan Combination of pravastatin and a fibric acid derivative, and method for treating dyslipidemia using such combination
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
FR2737121B1 (fr) 1995-07-27 1997-10-03 Cl Pharma Nouvelles formulations galeniques du fenofibrate et leurs applications
AU752673B2 (en) * 1997-07-31 2002-09-26 Abbott Laboratories Combinations of HMG-CoA reductase inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a day at night

Also Published As

Publication number Publication date
HN1999000208A (es) 2000-11-22
CN1330544A (zh) 2002-01-09
WO2000037078A1 (de) 2000-06-29
PL349389A1 (en) 2002-07-15
AU3035600A (en) 2000-07-12
GT199900214A (es) 2001-06-08
CA2355295A1 (en) 2000-06-29
IL143221A0 (en) 2002-04-21
US6511985B1 (en) 2003-01-28
CO5160272A1 (es) 2002-05-30
TR200101722T2 (tr) 2001-11-21
SV1999000250A (es) 2000-10-16
AR021643A1 (es) 2002-07-31
KR20010093845A (ko) 2001-10-29
EP1140082A1 (de) 2001-10-10
PE20001325A1 (es) 2000-12-30
ZA200103918B (en) 2002-05-15
DE19858789A1 (de) 2000-06-21

Similar Documents

Publication Publication Date Title
BR9916270A (pt) Combinação de cerivastatina e fibratos
BR9712652A (pt) Tienopirimidinas possuindo ação inibidora de pde v.
SE0001899D0 (sv) New compounds
BR0013122A (pt) Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina
MEP42808A (en) Use of flibanserin in the treatment of sexual disorders
BR0314603A (pt) Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
BR9809819A (pt) Compostos e métodos para a inibição da expressão de vcam-1
DE60037578D1 (de) Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen
BR0316438A (pt) Uso de eritropoietina em doenças cardìacas
BR0114913A (pt) Inibidores de metaloproteinase de espiro-pirimidina-2,4,6-triona
UY28041A1 (es) Metodos de dosis bajas para el tratamiento de trastornos en los cuales la actividad del tnfa es perjudicial.
BR0207726A (pt) Sais farmacêuticos
BR0312232A (pt) Inibidores de caspases e seus usos
DE60228722D1 (de) Zusammensetzung und ihre verwendungszwecke zur bekämpfung von kater
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
NO20014240L (no) C16-umettede FP-selektive prostaglandinanaloger
BR9810616A (pt) Inibidores de farnesil transferase em combinação com inibidores de hmg coa redutase para o tratamento do cancer
ES2141330T3 (es) Monohidrato de (e)-2&#39;-desoxi-2&#39;-(fluorometileno)citidina.
BG106748A (en) Method and compositions for treating pulmonary diseases
BR0010699A (pt) Benzimidazóis substituìdos, sua produção e utilização dos mesmos como agente contra protozoários parasitários
HRP20050611B1 (hr) Kombinacijski lijek
BR0007183A (pt) Isonipectoamidas para o tratamento de distúrbios mediados por integrina
PL1498119T3 (pl) Zastosowanie sprzężonych dienów kwasu linolowego do leczenia przeziębienia
MXPA04002492A (es) Uso novedoso de aminometil cromanos sustituidos.
BRPI0417140A (pt) derivados quinolina ácidos e seu uso na prevenção e/ou tratamento de patologias relacionadas com hiperglicemia

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]